TamirBio

First-in-Class Therapeutics Against Viral Infections

TamirBio was a clinical-stage biopharma company developing antiviral therapeutics for viral and autoimmune diseases.

TamirBio’s lead asset, ranpirnase, an RNA-degrading enzyme, regulates cell processes and offers anti-proliferative and apoptotic properties. The company’s initial focus was on HPV, the most common STI with 14 million cases annually. The company was creating a safe, innovative topical treatment requiring just 1-2 applications to address current treatment gaps.

SECTOR

Health Sciences

INVESTED

2018

STATUS

Acquired by Orgenesis (2020)

HQ

Short Hills, NJ

FOUNDERS

Kuslima Shogen

Subscribe to hear about Arc Ventures' updates and events.